Sum Trading At: ,Primary Metric per Equity / Cash Flow Line Item.: ($9.548,912) M, 29.3 ,Metric Weighted per Price Range / Change, 6.66_4_304 ,Combined Weight Adj Trade Metric, 38.99_22 ,for -($1.4)M Market Cap, for, (0.02) off .08;
Equity $$MM: (10) MinRetGrowth: 0.09 MinRetInv: 0.05 Weighted Cost of Capital: 81.785% Estimated Local Continuing Value, Buyout in $$M: 10.607 Estimated Factor NOT LOCAL in $$M: 0.200136 Estimated ContinuingValue: Annual Sales / Top Line Revenue, Desired / Avg per Buyer$$M: 2.122749 Est Buyout Price : 0.1403_53 0.03, ,Annual Sales Factor Forward. 4.607_12_22, ,Price To. 4.498 Year Turnover Period; Year End 2010 Sales 2M;
Profile: Founded in 1998, with the initial development of its intellectual property base in 1992, BioLife Solutions develops, manufactures, and markets patented hypothermic storage/transport and cryopreservation (freeze) products for cells, tissues, and organs, and also performs contract media manufacturing and contract research and development. The Company's proprietary HypoThermosol and CryoStor platform of biopreservation products are marketed to academic research institutions, hospitals, and commercial companies involved in cell therapy, tissue engineering, cord blood banking, drug discovery, and toxicology testing. BioLife's GMP products are serum-free and protein-free, fully defined, and pre-formulated to reduce preservation-induced, delayed-onset cell damage and death.
I like the company; Looking for 3.75 to 4.75 Cents with Volume...[10Q Equity @ (10.100405M) and there could be a merger or acquirer transaction;ie;Still Trade As BLFS; [Speculation per buyout, but Private Equity Buyouts have been doing rather well lately with companies such as BLFS;]